Pharmacokinetics of human insulin zinc suspension (recombinant DNA) in normal man: a comparison with porcine insulin zinc suspension.
A single dose crossover study in 10 fasting, non-diabetic men compared the 24-hour profiles of blood glucose, plasma insulin, and C-peptide following a single subcutaneous injection of either human insulin zinc suspension crystalline (recombinant DNA), or highly purified porcine insulin zinc suspension (mixed), in a standard dose of 0.2 U/kg. Both insulins produced moderate hypoglycaemia within 3 hours which persisted for 24 hours after administration. The rate of fall of blood glucose was similar from 0-3 hours but was significantly lower after the porcine insulin at 4 and 7 hours (p less than 0.05). Mean plasma insulin values were higher after porcine insulin between 2 and 6 hours (p less than 0.05) and a biphasic pattern was observed following injection of both insulins. Plasma C-peptide declined after each insulin was administered, and was significantly lower between 2 and 7 hours after porcine insulin. The duration of the hypoglycaemic action of human crystalline insulin (recombinant DNA), assessed by blood glucose measurements and C-peptide suppression, was equivalent to porcine insulin zinc suspension (mixed) (Monotard MC, Novo) over 24 hours.
D000328:Adult; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D002096:C-Peptide / Q000097:blood; D004274:DNA, Recombinant / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000097:blood; D049528:Insulin, Long-Acting / Q000378:metabolism* / Q000627:therapeutic use; D007700:Kinetics; D008297:Male; D011994:Recombinant Proteins / Q000378:metabolism* / Q000627:therapeutic use; D012107:Research Design; D013552:Swine
D001786:Blood Glucose; D002096:C-Peptide; D004274:DNA, Recombinant; D007328:Insulin; D049528:Insulin, Long-Acting; D011994:Recombinant Proteins